# EDGAR Filing Document

**Accession Number:** 0001505512
**File Stem:** 0001104659-25-065915
**Filing Date:** 2025-7
**Character Count:** 2837
**Document Hash:** 884f7649c4ec8eb70ad3102a68330fa4
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001104659-25-065915.hdr.sgml**: 20250707

**ACCESSION NUMBER**: 0001104659-25-065915

**CONFORMED SUBMISSION TYPE**: 15-12G

**PUBLIC DOCUMENT COUNT**: 1

**FILED AS OF DATE**: 20250707

**DATE AS OF CHANGE**: 20250707

**EFFECTIVENESS DATE**: 20250707

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Regulus Therapeutics Inc.
- **CENTRAL INDEX KEY:** 0001505512
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 264738379
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 15-12G
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-35670
- **FILM NUMBER:** 251106894

**BUSINESS ADDRESS:**
- **STREET 1:** 4224 CAMPUS POINT COURT
- **STREET 2:** SUITE 210
- **CITY:** SAN DIEGO
- **STATE:** CA
- **ZIP:** 92121
- **BUSINESS PHONE:** 858-202-6300

**MAIL ADDRESS:**
- **STREET 1:** 4224 CAMPUS POINT COURT
- **STREET 2:** SUITE 210
- **CITY:** SAN DIEGO
- **STATE:** CA
- **ZIP:** 92121

**UNITED STATES<br> SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**FORM 15**

**CERTIFICATION AND NOTICE OF TERMINATION OF REGISTRATION<br> UNDER SECTION 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934<br> OR SUSPENSION OF DUTY TO FILE REPORTS UNDER SECTIONS 13 AND 15(d)<br> OF THE SECURITIES EXCHANGE ACT OF 1934**

**Commission File Number: 001-35670**

**Regulus Therapeutics Inc.**

**(Exact name of registrant as specified in its charter)**

**4224 Campus Point Court, Suite 210**

**San Diego, CA 92121**

**(858) 202-6300<br> (Address, including zip code, and telephone number, including area code, of registrant's principal executive offices)**

**Common Stock, par value $0.001 per share<br> (Title of each class of securities covered by this Form)**

**None<br> (Titles of all other classes of securities for which a duty to file reports under section 13(a) or 15(d) remains)**

Please place an X in the box(es) to designate the appropriate rule provision(s) relied upon to terminate or suspend the duty to file reports:

---

| | |
|:---|:---|
| Rule 12g-4(a)(1) | ⌧ |
| Rule 12g-4(a)(2) | ¨ |
| Rule 12h-3(b)(1)(i) | x |
| Rule 12h-3(b)(1)(ii) | ¨ |
| Rule 15d-6 | ¨ |
| Rule 15d-22(b) | ¨ |

---

Approximate number of holders of record as of the certification or notice date: One (1)

Pursuant to the requirements of the Securities Exchange Act of 1934, Regulus Therapeutics Inc. has caused this certification/notice to be signed on its behalf by the undersigned duly authorized person.

---

| | | | |
|:---|:---|:---|:---|
|  | REGULUS THERAPEUTICS INC. | REGULUS THERAPEUTICS INC. | REGULUS THERAPEUTICS INC. |
| Date: July 7, 2025 | By: | /s/ Jaime Huertas | /s/ Jaime Huertas |
|  |  | Name: | Jaime Huertas |
|  |  | Title: | Secretary |

---